
美国食品药品监督管理局(FDA)已指出,用于减重和糖尿病的GLP-1药物可能与一种罕见眼部疾病的风险增加相关。诺和诺德公司的Wegovy和礼来公司的Zepbound是被点名的药物之一。该机构表示,正在继续审查安全性数据。
The U.S. Food and Drug Administration has flagged a potential increased risk of a rare eye condition linked to GLP-1 drugs used for weight loss and diabetes. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are among the medicines named in the warning. The agency says it is continuing to review safety data.
美国食品药品监督管理局表示,已发现证据表明,服用GLP-1药物(一类包括司美格鲁肽和替尔泊肽的药物)的患者患罕见眼部疾病的风险可能增加。由诺和诺德生产的Wegovy和由礼来生产的Zepbound是体重管理和2型糖尿病处方量最大的药物之一。
The FDA said it has found evidence pointing to a potentially increased risk of a rare eye condition among patients taking GLP-1 medications, a drug class that includes semaglutide and tirzepatide. Wegovy, made by Novo Nordisk, and Zepbound, made by Eli Lilly, rank among the most widely prescribed drugs for weight management and type 2 diabetes.
近年来,GLP-1药物已成为制药行业增长最快的板块之一,患者和保险公司的需求屡次超过供应。随着使用量攀升至数千万张处方,监管机构一直在稳步审查副作用报告,从胃肠道不适到甲状腺问题,现在又扩展到眼部健康。
GLP-1 drugs have become one of the pharmaceutical industry's fastest-growing segments in recent years, with demand from patients and insurers repeatedly outpacing supply. As usage has climbed into the tens of millions of prescriptions, regulators have steadily reviewed side-effect reports ranging from gastrointestinal complaints to thyroid concerns, and now eye health.
美国食品药品监督管理局表示,将继续监测安全性数据,且尚未下令召回或限制这两种药物的处方。诺和诺德和礼来尚未就这一具体发现发表公开评论。建议患者将任何视力变化与医生讨论,而不是自行停止治疗。
The FDA said it will keep monitoring safety data and has not ordered a recall or restricted prescribing of either drug. Novo Nordisk and Eli Lilly have not issued public comment on the specific finding. Patients are advised to discuss any vision changes with a physician rather than stop treatment on their own.